Quantcast
Channel: WN.com - Articles related to Actelion to enter Phase II clinical development with new dual orexin receptor antagonist in patients with insomnia (Actelion Ltd)
Viewing all articles
Browse latest Browse all 480

Actelion's Chief Scientific Officer Martine Clozel awarded the Tomoh Masaki award by the 14th International ...

$
0
0
(Source: Actelion Ltd) SAVANNAH, UNITED STATES OF AMERICA AND ALLSCHWIL, SWITZERLAND - 05 September 2015 - Actelion Ltd (SIX: ATLN) today announced that its Chief Scientific Officer and Member of the Actelion Founding team, Martine Clozel, has been awarded the Tomoh Masaki Award by the International Conferences on Endothelin, the bi-annual scientific event, currently taking place for the 14th time in Savannah, Georgia/USA. In its tribute, the award committee highlighted Dr. Clozel's contribution to successfully discovering multiple endothelin receptor antagonists, especially Tracleer® (bosentan) and Opsumit® (macitentan), two molecules that each made history in the field of pulmonary...

Viewing all articles
Browse latest Browse all 480

Trending Articles